The tolerability of venlafaxine

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 5, 1998, Pages 333-344

  Sinclair, Julia ^a   Birtwistle, Jon ^a   Baldwin, David ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; ANTIDEPRESSANT AGENT; BENZATROPINE; CISAPRIDE; CLOMIPRAMINE; CYTOCHROME P450; DESVENLAFAXINE; DOSULEPIN; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ADVERSE DRUG REACTION; AGED; ARTICLE; ASTHENIA; BONE DISEASE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG TOLERABILITY; EAR DISEASE; ENZYME INHIBITION; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MENTAL DISEASE; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PREGNANCY; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; SKIN MANIFESTATION; SOMNOLENCE; SWEATING; XEROSTOMIA;

EID: 0031872363     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Adler LA, Resnick S, Kunz M, Devinsky O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995; 31: 785-788.
2. Aguiar L, Derivan AT, for the Venlafaxine XR 209 Study Group. Once-daily venlafaxine extended release (XR) in outpatients with major depression. Presented at the 6th World Congress of Biological Psychiatry. Nice, 22-27 June, 1997.
3. Ahmad S. Venlafaxine and severe tinnitus. Am Fam Physician 1995; 51: 1830.
4. Amchin J, Zarycranski W, Taylor K. Venlafaxine's lack of CYP3A4 inhibition assessed by terfenadine metabolism. Clin Pharmacol Ther 1997a; 61: 179.
5. Amchin J, Zarycranski W, Taylor K. Evidence that venlafaxine does not inhibit CYP1A2 as measured in vivo by the metabolism of caffeine. Clin Pharmacol Ther 1997b; 61: 179.
6. Anderson I. Lessons to be learnt from meta-analyses of newer versus older antidepressants. Adv Psychiatr Treat 1997; 3: 58-63.
7. Baldwin DS, Rudge SE. The tolerability of moclobemide. Rev Contemp Pharmacother 1994; 5: 57-65.
8. Baldwin DS, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991; 6: 51-58.
9. Baldwin DS, Thomas SC, Birtwistle J. Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Pract 1997; 1: 47-58.
10. Ball S, Ahern D, Kao J, Acatina J. Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation; comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4, and CYP2C09. Clin Pharmacol Ther 1996; 59: 170.
11. Benazzi F. Venlafaxine withdrawal symptoms. Can J Psychiatry 1996; 41: 487.
12. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30: 441-451.
13. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol 1996; 38: 358-361.
14. Burnett FE, Dinan TG. The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 1998; 9: 303-320.
15. Cavanaugh GL, Martin RE, Stenson MA, Robinson DD. Venlafaxine and urinary incontinence: possible association. Ann Pharmacother 1997; 31: 372.
16. Clerc GE, Ruimy P, Verdeau Pailles J, on behalf of the French In-patient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139-143.
17. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99-106.
18. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995; 10 (Suppl 2): 15-20.